Ed Silverman’s Pharmalot column noted a single personnel move: Cerevance has hired Karl Kieburtz as its chief medical officer. The mention appears as the featured person in this week’s coming-and-going roundup. The item is concise and presents the appointment as the primary news peg for the column’s weekly personnel highlight.
The write-up did not expand on the hire beyond naming the company and the executive. The article offers no job description, no account of the responsibilities that Mr. Kieburtz will assume, and no timeline for when he began or will begin the role. The source did not include quotes from company representatives, the appointee, or independent observers.
The announcement ran in Pharmalot and is labeled a STAT+ exclusive. The published page indicates that the remainder of the story is available only to STAT+ subscribers and directs readers to log in or subscribe to read the full content. The public-facing portion of the item contains the key personnel note but omits any extended analysis or background that may appear behind the paywall.
The presentation also situates the appointment inside a familiar Pharmalot feature: a compact roundup of comings and goings in biotech and pharma where the column highlights a different individual each week. Readers encountering the publicly visible excerpt will find the short notice and the subscription prompt; they will not find further reporting unless they access the paid content.
The article reiterates Pharmalot’s longstanding call for reader-submitted personnel updates. The column explicitly invites readers to send notices when they hire new staff, promote rising talent, or fill difficult positions. The line reads as an open invitation: send your changes and Pharmalot will consider publishing them. The piece frames this as a routine, community-sourced input mechanism rather than a formal press-release pipeline.
This solicitation appears adjacent to the personnel notice and acts as a regular feature of the column’s format. The public excerpt urges contributors not to be shy, noting that Pharmalot will find a place for submitted changes. No editorial standards, submission guidelines, or contact protocol were detailed in the visible text; the source did not provide a submission email address or a step-by-step process for contributing items beyond the general invitation.
The source content is brief and selective. It did not provide:
The article’s byline and metadata were published with a date and author attribution; however, beyond naming the appointment and indicating that this item is the weekly highlighted person, no methodological or corroborating details were offered in the publicly visible excerpt. If readers require fuller reporting — for example, a professional biography, a statement from the company, or background on strategic intent — those elements were not present in the source text and would require access to the subscriber-only portion of the article or direct inquiry to the company.
Limitations and next steps
The information available in the source is narrowly focused and paywalled. Investigators seeking more comprehensive reporting should consult the full STAT+ article or contact Cerevance’s communications office for confirmation, biography, and role specifics. The Pharmalot column itself advises industry contacts to submit personnel changes for future coverage; the source did not provide a detailed submission process in the visible text.
No further data, timelines, trial information, or clinical details were included in the source. The reader should treat the item as a brief personnel notice rather than an in-depth profile or a report that addresses clinical programs, regulatory activity, or trial outcomes.